These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32522210)

  • 1. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.
    Versfeld A; McBride A; Scheibe A; Spearman CW
    Harm Reduct J; 2020 Jun; 17(1):39. PubMed ID: 32522210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016.
    Mittal A; Kosinski KC; Stopka TJ
    Harm Reduct J; 2019 Jul; 16(1):44. PubMed ID: 31288811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "I want to feel young again": experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada.
    Jacob J; Goodyear T; Coulaud PJ; Hoong P; Ti L; Knight R
    Can J Public Health; 2021 Oct; 112(5):947-956. PubMed ID: 34115340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to and acceptability of sexual and reproductive health, harm reduction and other essential health services among people who inject drugs in Durban, South Africa.
    Milford C; Cavanagh T; Bosman S; Wilson M; Smit J; Zanoni B
    Harm Reduct J; 2024 Jun; 21(1):123. PubMed ID: 38926755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Bahramnejad A; Barshan A; Mousavian G; Najafi E; Sharifi H; Haghdoost AA; Briceno A; McFarland W; Page K
    Subst Abuse Treat Prev Policy; 2020 Aug; 15(1):56. PubMed ID: 32758246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting.
    Yela E; Solé N; Puig L; López Gallegos D; Clua-García R
    Harm Reduct J; 2024 Apr; 21(1):88. PubMed ID: 38678266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and best practices for hepatitis C care among people who inject drugs in resource limited settings: focus group discussions with healthcare providers in Kenya.
    Seu R; Riback LR; Nyakowa M; Lizcano J; Musyoki H; Ross J; Cherutich P; Kurth AE; Akiyama MJ
    Glob Public Health; 2022 Dec; 17(12):3627-3637. PubMed ID: 35941717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Drug Policy; 2021 Oct; 96():103238. PubMed ID: 33902968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
    Childs E; Assoumou SA; Biello KB; Biancarelli DL; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Bazzi AR
    Harm Reduct J; 2019 Feb; 16(1):14. PubMed ID: 30744628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.
    Saayman E; Hechter V; Kayuni N; Sonderup MW
    Harm Reduct J; 2023 Mar; 20(1):27. PubMed ID: 36870990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration.
    Ward KM; McCormick SD; Sulkowski M; Latkin C; Chander G; Falade-Nwulia O
    Int J Drug Policy; 2021 Feb; 88():103019. PubMed ID: 33160152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service.
    Phillips C; Schulkind J; O'Sullivan M; Edelman N; Smith HE; Verma S; Jones CJ
    J Viral Hepat; 2020 Feb; 27(2):176-187. PubMed ID: 31566851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan.
    Martínez-Pérez GZ; Nikitin DS; Bessonova A; Fajardo E; Bessonov S; Shilton S
    BMC Infect Dis; 2021 Jun; 21(1):609. PubMed ID: 34171990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore.
    Falade-Nwulia O; Irvin R; Merkow A; Sulkowski M; Niculescu A; Olsen Y; Stoller K; Thomas DL; Latkin C; Mehta SH
    J Subst Abuse Treat; 2019 May; 100():45-51. PubMed ID: 30898327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.